Tag: Implant

25. October 2022

AMW and Mistral sign License and Supply Agreement for Commercialization of AMW’s Goserelin and Leuprorelin implants

AMW GmbH, a specialty pharmaceutical company focused on innovative sustained-release drug delivery systems, and Mistral Capital Management Ltd, a pharmaceutical company specialized in distribution and promotion of high-quality medicines, today announced that they have entered into a semi-exclusive license and supply agreement (LSA) for the commercialization of AMW’s goserelin and leuprorelin implants in two countries, including Ukraine.

13. July 2022

Further marketing approvals for AMW’s goserelin implant for the treatment of hormone-sensitive tumors in the EU and Central America

AMW GmbH, a pharmaceutical company specializing in innovative drug delivery systems, announced today that its proprietary goserelin implant has received two additional marketing approvals in one country each in the European Union and Central America. AMW’s goserelin implant is the only approved generic implant version to date for AstraZeneca’s originator product Zoladex®1. Goserelin enables symptomatic therapy of hormone-sensitive tumors, such as prostate or breast cancer, as well as certain gynecological diseases. AMW’s goserelin implant is now available to patients in approximately 30 countries worldwide as a cost-effective alternative therapy.

4. November 2015

For the biodegradable goserelin implants 3.6 mg and 10.8 mg developed by AMW GmbH and clinically tested, the national approval was obtained today as part of a DCP procedure.

The products are characterized by innovative applicators. Handling is easier, misapplications and painful injections are avoided.